Key TakeawaysUS 30-year fixed mortgage rates fell to 5.98%, dropping below the 6% threshold for the first time since September 2022.The US Navy’s 5th Fleet in Bahrain has been reduced to mission-critical staffing of under 100 personnel amid escalating tensions and potential strikes involving Iran.The US International Trade Commission (ITC) launched a fact-finding probe to assess the economic impact of revoking China's Permanent Normal Trade Relations (PNTR) status.Bayer (BAYRY) reported that its PEACE-3 tri ...

"Company†) (NASDAQ: NAVN) common stock pursuant and/or traceable to the Registration Statement issued in connection with the Company's October 31, 2025 initial public offering (the "IPO†or the "Offering†). Navan investors ha...## Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm, Encourages Lakeland Industries, Inc. (LAKE) Shareholders To Inquire About Securities Fraud Class ActionLOS ANGELES--([BUSINESS WIRE])--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder right ...

Grifols doubles net profit in 2025, driven by revenues | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]The logo of the Spanish pharmaceuticals company Grifols is pictured on theirs facilities in Parets del Valles, north of Barcelona, Spain, January 9, 2024. REUTERS/Albert Gea [Purchase Licensing Rights, opens new tab]- Companies[Grifols SA]FollowBARCELONA, Feb 26 (Reuters) - Spanish drugmaker Grifols [(GRLS.MC), opens new tab] repo ...

Key Takeaways MIRM reported Q4 loss of 11 cents, but revenues beat estimates, rising 50% Y/Y to $148.9M.MIRM Q4 2025 sales were driven by Livmarli and newly acquired Cholbam and Ctexli products.MIRM guides 2026 net product sales of $630-$650M, eyes positive cash flow in 2027.Mirum Pharmaceuticals (MIRM) reported a loss of 11 cents per share in fourth-quarter 2025, against the Zacks Consensus Estimate of earnings of 2 cents. The company reported a loss of 49 cents per share in the year-ago quarter.Revenues i ...

Key Takeaways IRWD posted Q4 loss and revenue miss, with sales down 47% and shares sliding 11%.Ironwood's Linzess profit share declined 49% as U.S. net sales dropped 27% Y/Y in Q4 2025.IRWD reaffirmed 2026 revenue outlook of $450M-$475M and continues to see EBITDA above $300M.Ironwood Pharmaceuticals (IRWD) reported an adjusted loss of 1 cent per share for the fourth quarter of 2025, against the Zacks Consensus Estimate of earnings of 2 cents. The company had reported adjusted earnings of 1 cent per share i ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer's XOFIGO® plus enzalutamide demonstrates significant OS benefit in PEACE-3 trial in patients with mCRPC with bone metastases. ...

In this article, we will look at the 11 Best Strong Buy Healthcare Stocks to Invest In.On February 23, Steven Wieting, CIO Group chief investment strategist, appeared on CNBC’s ‘The Exchange’ to talk about the stock market and the recent price action in stocks. CNBC reported that staples, healthcare, and utilities are all leading, outperforming since January 1 and showing that this is not a one-day trend but has rather been going on since the turn of the calendar. Wieting stated that a lot is going on in th ...

Key Takeaways CPRX beat Q4 estimates with 68 cent EPS and $152.6M in revenues, up 8% year over year.Firdapse sales rose 18% to $97.6M, while Agamree revenues jumped 68% in the quarter.2026 revenue guidance of $615M-$645M reflects growth in Firdapse and Agamree sales.Catalyst Pharmaceuticals (CPRX) reported adjusted earnings of 68 cents per share for the fourth quarter of 2025, beating the Zacks Consensus Estimate of 42 cents. The company had recorded adjusted earnings of 70 cents in the year-ago quarter.Tot ...

Innoviva Conference Call Summary Company Overview - Innoviva was originally formed to manage royalty revenues from products developed with GSK, focusing on creating shareholder value through diversified business areas [1] - The company consists of three main components: 1. Royalty business from respiratory assets Breo and ANORO, generating $250 million in gross royalty revenue last year [2] 2. Specialty therapeutics business (Innoviva Specialty Therapeutics, IST), which delivered nearly $120 million in US sales last year and is expected to generate at least $150 million this year [2] 3. A diversified portfolio of strategic healthcare assets valued at over $600 million [3] Financial Performance - Innoviva reported strong Q4 earnings, showcasing growth across all business segments and strong momentum heading into 2026 [3] - IST business achieved its best quarter ever with $34 million in U.S. sales, marking three consecutive years of 50% annual growth [4] - The royalty business outperformed expectations, contributing to overall resilience [4] Capital Allocation Strategy - Innoviva has a cash position of over $500 million, allowing for attractive opportunities for value creation through capital deployment [6] - Plans include investing in organic growth for IST, supporting strategic healthcare assets, and evaluating new investments for long-term value [6][8] - A $125 million share buyback program was announced, reflecting commitment to shareholders and confidence in growth prospects [9] Strategic Healthcare Assets - Armata, a portfolio company, is a market leader in bacteriophage therapeutics, with a 100% clinical cure rate in a Phase 2 trial for Staph aureus bacteremia [10] - The company is excited about Armata's plans to initiate a Phase 3 study, which could lead to significant market changes [11] Growth Opportunities - The therapeutic business is in a high growth period, with potential for both organic and inorganic growth [12] - The strategic healthcare assets are expected to provide asymmetric payoffs with beneficial risk-reward profiles [13] Product Updates - ZEVTERA, approved for treating bacterial infections, is in the early stages of market penetration with positive feedback from the medical community [15][16] - Zoliflodacin (NUZOLVENCE) is set for commercialization in the second half of the year, focusing on outpatient providers [18][19] - Peak sales expectations for IST products include: - GIAPREZA: $150 million potential, with $72 million in 2025 sales [23] - Zegdura: Expected to reach $150 million-$200 million, with $33 million in 2025 sales [25] - XERAVA: Stable revenue source with lower growth rates anticipated [26] - ZEVTERA: Expected to show good revenue trajectory in the second half of the year [27] - NUZOLVENCE: Total addressable market could be as large as $500 million [28] Underappreciated Aspects - Innoviva's ability to succeed in various economic environments due to strong cash flows and diversified business model [29] - Growth potential in strategic healthcare assets, particularly with Armata and other investments [31][32] Future Outlook - 2026 is anticipated to be an exciting year with multiple catalysts, including Armata's Phase 3 trial and potential Phase 2 readout from Syndeio [33][34] - Continued focus on growing the IST portfolio and launching new products [34][35]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. Beijing Wehand-Bio Pharmaceutical Co., Ltd.* 北 京 五 和 博 澳 藥 業 股 份 有 限 公 司 (A joint stock company incorporated in the People's Republic of China wit ...